OMT Announces New Antibody Discovery Program
Complete the form below to unlock access to ALL audio articles.
Open Monoclonal Technology, Inc. (OMT) has announced an antibody discovery collaboration with Merck KGaA.
OMT and Merck KGaA have entered into a collaboration whereby OMT will use its OmniRats™ to generate antibodies against several targets selected by Merck KGaA.
Merck KGaA has the rights to further develop and commercialize the antibodies derived from the OmniRat™ as therapeutic and diagnostic products.
Under the terms of the agreement, OMT will receive upfront payment, success-based milestones, and royalties.
"We are pleased to be collaborating with Merck KGaA. OMT's OmniRat™ generates antibodies with great specificity, affinity and manufacturability. Our partners are looking for technologies that can eliminate time-consuming humanization of antibodies or optimization of leads identified using display technology. The OmniRat™ can save significant development time and is available for all targets", said Roland Buelow, Founder and CEO of OMT.
